ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered
$IBRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer
- ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on cytokines and natural killer (NK) cells
- ANKTIVA's novel mechanism of action activates the body's immune system of natural killer and killer T cells to attack BCG resistant tumor cells and induce memory T cells resulting in a long duration of complete response exceeding 47 months1
- ANKTIVA reimbursement now covered by multiple healthcare plans
- Urologists treating eligible bladder cancer patients can learn more about the treatment option and access support program ImmunityBio CARE™ at Anktiva.com